# JAKAFI XR
> **NDA217180** · New Drug Application · Sponsor: INCYTE CORP · Approved 2026-05-01
## Drug
- **FDA Application Number:** NDA217180
- **Application type:** New Drug Application
- **Brand name:** JAKAFI XR
- **Generic name:** RUXOLITINIB
- **Active ingredients:** RUXOLITINIB PHOSPHATE
- **Dosage form:** TABLET, EXTENDED RELEASE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** INCYTE CORP
- **Manufacturer:** Incyte Corporation
- **First approval:** 2026-05-01
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217180)
---
*MORVS · CC0 1.0*